Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Montelukast In Children with Sickle Cell Disease (SMILES)
2017-004539-36Phase 2Unknown
- Sponsor
- Great Ormond Street Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of montelukast in sickle cell disease (SCD), sleep disordered breathing (SDB) and obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Great Ormond Street Hospital. Primary endpoints: Neurocognition processing speed (Cancellation - Wechsler scales) and Neurocognition processing speed (NIH Toolbox processing speed). Status: unknown.
02
Drugs
montelukast
03
Conditions
sickle cell disease (SCD)sleep disordered breathing (SDB)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2017-004539-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004539-36.